Evidence map›Paper›PMID 31149480›Full record

ArticleInternational cancer conference journal2017

Effect of anti-PD-1 antibody, nivolumab on early gastric cancer.

Koji Fukuda, Taichi Yoshida, Kazuhiro Shimazu, Daiki Taguchi, Masahiro Inoue, Hiroshi Nanjyo, Hiroyuki Shibata

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in International cancer conference journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Koji FukudaAkita University, Akita, Japan.
Taichi YoshidaAkita University, Akita, Japan.
Kazuhiro ShimazuAkita University, Akita, Japan.
Daiki TaguchiAkita University, Akita, Japan.
Masahiro InoueAkita University, Akita, Japan.
Hiroshi NanjyoAkita University, Akita, Japan.
Hiroyuki ShibataAkita University, Akita, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunomodulation treatment using anti-programmed cell death protein 1 antibody is a very promising treatment for various types of advanced cancers, including melanoma, non-small cell lung cancer, and renal cell carcinoma. However, the therapeutic effects on early cancers are still unknown. We experienced 2 cases of early gastric cancers coexisting advanced melanomas. In both cases, early gastric cancers did not respond to nivolumab. Both early gastric cancers did not express programed death ligand 1. It was speculated that immunotolerance was not fully established responsible for nivolumab in early gastric cancer, and for this reason, nivolumab could not shrink these tumors. We experienced 2 cases of early gastric cancer, where PD-L1 was negative, not responding to nivolumab.

Indexed as

Anti-PD-1 antibodyEarly gastric cancerNivolumab

Identifiers

PMID31149480
PMCPMC6498353

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.